Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study
- PMID: 31396074
- PMCID: PMC6668630
- DOI: 10.3389/fnagi.2019.00176
Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study
Abstract
Background: To study the extent to which neuropsychiatric symptoms (NPS) influence the cognitive and functional decline in frontotemporal degeneration (FTD) and Alzheimer's disease (AD). Methods: We assessed the progression of NPS and their influence on cognitive and functional progression in a group of FTD (n = 36) and AD patients (n = 47) at two different stages of the disease (2.5 years). A standardized scale was used to assess NPS-the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD)-which tracks different symptoms including depression, psychotic symptoms, as well as sleep and conduct problems. In addition, in a subsample of patients (AD n = 14 and FTD n = 14), we analyzed another group of NPS by using the Neuropsychiatric Inventory (NPI). Cognitive declines were tracked by using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while functionality was tracked by using the Lawton scale and the Barthel Index. Results: The presence of NPS impacts cognitive and functional decline in both groups of patients 2.5 years after disease onset. However, we observed a dissociable profile of the affectation of NPS in each group. In the AD group, results indicate that the progression of depressive symptoms and sleep problems predict cognitive and functional decline. In contrast, the progression of a mixed group of NPS, including conduct problems and delusions, predicts cognitive and functional decline in FTD. Conclusion: The presence of NPS has a critical impact on the prediction of cognitive decline in FTD and AD patients after 2.5 years of disease progression. Our results demonstrate the importance of assessing different types of NPS in neurodegenerative disorders which, in turn, predict disease progression. Future studies should assess the role of NPS in predicting different neurocognitive pathways and in neurodegeneration.
Keywords: Alzheimer’s disease; assessment of cognitive disorders/dementia; behavioral disturbances; cohort studies; depression; frontotemporal dementia.
Similar articles
-
Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEM-Austria).J Alzheimers Dis. 2020;73(1):125-133. doi: 10.3233/JAD-190662. J Alzheimers Dis. 2020. PMID: 31744004
-
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China.Aging Ment Health. 2017 Jun;21(6):651-657. doi: 10.1080/13607863.2016.1146871. Epub 2016 Feb 16. Aging Ment Health. 2017. PMID: 26882509
-
Prevalence of neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease, and its relationship with cognitive impairment.Curr Alzheimer Res. 2010 Sep;7(6):517-26. doi: 10.2174/156720510792231748. Curr Alzheimer Res. 2010. PMID: 20455862
-
Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia.Front Pharmacol. 2019 Nov 22;10:1398. doi: 10.3389/fphar.2019.01398. eCollection 2019. Front Pharmacol. 2019. PMID: 31824321 Free PMC article. Review.
-
Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.Ageing Res Rev. 2012 Jan;11(1):87-103. doi: 10.1016/j.arr.2011.06.005. Epub 2011 Jul 7. Ageing Res Rev. 2012. PMID: 21763789 Review.
Cited by
-
Effectiveness of psychological therapies for depression and anxiety in atypical dementia.Alzheimers Dement. 2024 Dec;20(12):8844-8854. doi: 10.1002/alz.14332. Epub 2024 Oct 23. Alzheimers Dement. 2024. PMID: 39439362 Free PMC article.
-
A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases.J Med Chem. 2023 Feb 23;66(4):2330-2346. doi: 10.1021/acs.jmedchem.2c01572. Epub 2023 Feb 14. J Med Chem. 2023. PMID: 36787643 Free PMC article. Review.
-
The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.Front Aging Neurosci. 2024 May 9;16:1382593. doi: 10.3389/fnagi.2024.1382593. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38784446 Free PMC article.
-
Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers-results from the DELCODE study.Alzheimers Res Ther. 2020 Oct 16;12(1):131. doi: 10.1186/s13195-020-00701-7. Alzheimers Res Ther. 2020. PMID: 33066827 Free PMC article.
-
Identification of biomarkers differentiating Alzheimer's disease from other neurodegenerative diseases by integrated bioinformatic analysis and machine-learning strategies.Front Mol Neurosci. 2023 May 10;16:1152279. doi: 10.3389/fnmol.2023.1152279. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37234685 Free PMC article.
References
-
- Atri A. (2011). Effective pharmacological management of Alzheimer’s disease. Am. J. Manag. Care 17, S346–S355. - PubMed
LinkOut - more resources
Full Text Sources